Renal Cancers Completed Phase 2 Trials for Sunitinib (DB01268)

Also known as: Renal Cancer / Kidney Cancer / Renal malignant neoplasm / Renal neoplasms malignant / Cancer of Kidney

IndicationStatusPhase
DBCOND0044624 (Renal Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02060370Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)Treatment
NCT00425386Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney CancerTreatment
NCT00459979Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by SurgeryTreatment
NCT00459875Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney CancerTreatment
NCT00462982Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or MelanomaTreatment
NCT00465179Sunitinib Malate in Patients With Non-Clear Cell Renal Cell CancerTreatment
NCT00814021Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the BrainTreatment
NCT01024205Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney CancerTreatment